Squamous cell carcinoma of the head and neck Trials in Atlanta, United States
Conditions / Squamous cell carcinoma of the head and neck / Atlanta, United States
Squamous cell carcinoma of the head and neck has been the subject of sustained clinical investigation across multiple research sites.
12 total trials for this combination
Showing top 10 of 12 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT03849469 | A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors | COMPLETED | PHASE1 |
| NCT02841748 | A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study | ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT02551159 | Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer | COMPLETED | PHASE3 |
| NCT03349710 | Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer | COMPLETED | PHASE3 |
| NCT01458392 | Study of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and Neck | COMPLETED | PHASE2 |
| NCT05783622 | Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies | RECRUITING | PHASE1 |
| NCT03517488 | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors | COMPLETED | PHASE1 |
| NCT02105636 | Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141) | COMPLETED | PHASE3 |
| NCT03752398 | A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) | COMPLETED | PHASE1 |
| NCT02543476 | SUPREME-HN A Retrospective Cohort Study of PD-L1 in Recurrent and Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) | COMPLETED | — |